Antineoplastic drugs develop from traditional single antineoplastic drug towards a new type of antineoplastic drug aiming at functions at multiple links. Research and development of antineoplastic drugs have stepped in to a new stage.
Till now, there are nearly four million cases of new tumors in China every year. With aging of population, environmental pollution caused by industrialization and lifestyles changed by factors like urbanization, malignant tumors replace cardiovascular diseases and become the top killer in China, taking 25% in total deaths.
For the increasing incidence of tumors, released needs for antineoplastic drugs and improving technologies for the drugs, output of the drugs will further increase in China. According to statistics of ASKCI, in 2015, total output of antineoplastic drugs was about 438 tonnes, with the market scale of around RMB100 billion. Sales of transnational enterprise were more centered and generally focused on promotion of their key products. While domestic enterprises applied the strategy of sales in a wide range.
In 2021, the forecast of China antineoplastic drug market will reach about RMB252 billion, relatively conservative compared to global market. Except adjuvant drugs like immunosuppressant, anti-metabolic will have the most market shares, with a stable growth. The second will be botanical preparations, remaining a relatively fast growth. Growth of alkylating agents, antibiotics and platinum drugs will tend to slow. As for targeted drugs, it is predicted that there is a large potential in independent R&D of targeted drugs, with the consideration of more supports by the government, and which will become the most important field leading domestic market of antineoplastic drugs.
In this report, AskCI will further disclose market potential and commercial opportunities for antineoplastic drug industry in China. Recommendations will be given at the end of the report to describe the prospect and provide suggestions for strategy making.
1)The Aim of Report
2)Benefit from the Report
2. SCOPE OF INVESTIGATION
The report will investigate Chinese antineoplastic drug industry from the following aspects:
3. Time Needed
Five work days needed
Table of Content
1 Overview of China Antineoplastic Drug Industry
1.1 Tumors in China
1.2 Supply and Demand
1.3 Competition Structure of China Antineoplastic Drug Industry
2 Sales Channels of Antineoplastic Drugs in China in 2015
3 Analysis of Major Companies of Antineoplastic Drugs in China
3.1 Jiangsu Hengrui Medicine Co., Ltd.
3.1.1 Development Analysis
3.1.2 Major Products
3.1.3 Operation Analysis
3.1.4 Competition Advantage
3.1.5 Sales Network
3.1.6 Development Strategy
3.2 CSPC Pharmaceutical Group Limited
3.3 Guizhou Yibai Pharmaceutical Co., Ltd.
3.4 Zhejiang HISUN Pharmaceutical Co., Ltd.
3.5 Beijing SL Pharmaceutical Co., Ltd.
3.6 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
4 Analysis of Antineoplastic Drugs by Subdivisions
5 Forecast of Antineoplastic Drug Industry in China, 2016-2021
6 Analysis of Investment and Financing Strategy Plan of Antineoplastic Drug Industry in China
6.1 Conclusion of Antineoplastic Drugs in China
6.2 Suggestions on Strategy Planning
6.2.1 Product Strategy
6.2.2 Channel Strategy
6.2.3 Development of Potential Market
6.2.4 Strategy of Market Competition
Table 1 Numbers of hospitals in China antineoplastic drug industry, 2011-2015
Table 2 Total outputs of China antineoplastic drug industry, 2011-2015
Table 3 Market scales and growth rates of China antineoplastic drug industry, 2011-2015
Figure 1 Numbers of drugstores in China, 2011-2015
Figure 2 Sales revenues of Zhejiang HISUN Pharmaceutical Co., Ltd., 2012-2016
Figure 3 Sales revenues of Guizhou Yibai Pharmaceutical Co., Ltd., 2012-2016
Make an enquiry before buying this Report
Please fill the enquiry form below.